BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15042312)

  • 1. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
    Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
    Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
    Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
    Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
    Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
    Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
    Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
    Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
    Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
    Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
    Meany HJ; Fox E; McCully C; Tucker C; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
    Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM
    Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.